Effect of preoperative lymphatic chemotherapy on Bcl-2 and Bax expression in axillary metastasis of breast cancer

Abstract

Abstract: Objective To observe the expression of Bcl-2 and Bax proteins and cell apoptosis induced by preoperative lymphatic chemotherapy with epirubicin-activated carbon suspension (Epi-CH) in the cells of axillary metastatic lymph node of breast cancer and investigate the mechanism. Methods Sixty patients with breast cancer of stages Ⅱ-Ⅲ were randomly divided into two groups. Forty patients in Epi-CH group were injected with 10 mg Epi-CH in the tissue around the primary tumor or biopsy excision 72 h before operation. Twenty patients in the control group were injected with 10 mg epirubicin solution in the same region. The stained lymph nodes full of tumor cells in Epi-CH group and the non-stained nodes in the control group were selected for apoptotic detection by TUNEL method. The expression of Bcl-2 and Bax proteins were examined by SP immunohistochemistry. Results The apoptotic index of the metastatic cancer cells in Epi-CH group was increased remarkably in comparison with that in the control group [(9.5±2.7) % vs (3.8±1.4) %, P<0.01). Compared with the control group, the expression of Bcl-2 and Bax proteins were up-regulated significantly in Epi-CH group (P<0.05 and P<0.01, respectively), resulting in decreased ratio of Bcl-2/Bax. Conclusion Lymphatic chemotherapy can promote cell apotosis in axillary metastasis of breast cancer, which may result from decreased ratio of Bcl-2/Bax.

CLC Number:

R737.9

WU Wu-jun¹, PAN Cheng-en¹, ZENG jian². Effect of preoperative lymphatic chemotherapy on Bcl-2 and Bax expression in axillary metastasis of breast cancer[J]. Journal of Southern Medical University, 2005, 25(08): 1001-1004.

References

[1] Giuliano AE, Barth AM, Spivack B, et al. Incidence and predictors of axillary metastasis in T1 carcinoma of the breast[J]. J Am Coll Surg, 1996, 183 (3): 185-9.
[2] Kobayashi O, Onodera S, Rino Y, et al. Evaluation of medicinal lymph node dissection in advanced gastric cancer[J]. Nippon Geka Gakkai Zasshi, 1994, 95(12): 860-5.
[3] Takahashi T, Hagiwara A, Shimotsuma M, et al. Prophylaxis and treatment of peritoneal carcinomatosis: intraperitoneal chemotherapy with mitomycin C bound to activated carbon particles[J].World J Surg, 1995, 19(4): 565-9.
[4] 许良中.实用肿瘤病理方法学[M].上海医科大学出版社,1997.253.
[5] Coleman MD. High dose chemotherapy: rationale and results in breast carcinoma[J]. Cancer, 2000, 88(12 Suppl): 3059-64.
[6] Scheithauer W, Clark GM, Salmon SE, et al. Model for estimation of clinically achievable plasma concentrations for investigational anticancer drugs in man[J]. Cancer Treat Rep, 1986, 70 (12):1379-82.
[7] 詹友庆,徐立,孙小卫,等.新辅助化疗对乳腺癌细胞凋亡和增殖的影响[J] 癌症,2002,21(2):186-8Zhan YQ, Xu L, Sun XW, et al. Affection of neoadjunvant chemotherapy on cell apoptosis and proliferation in breast cancer[J]. Chin J Cancer, 2002, 21(2):186-8.
[8] 邵志敏,李俊,吴昊,等.术前化疗诱导乳腺癌细胞凋亡的临床意义[J].中华肿瘤杂志,2000,22(4):295-7.Shao ZM, Li J, Wu H, et al. Clinical implication ofapoptosis of breast cancer induced by preoperative chemotherapy[J]. Chin J Oncol, 2000, 22(4): 295-7.
[9] Warnberg F, Nordgren H, Bergkvist L, et al. Tumor markers in breast carcinoma correlate with grade rather than with invasiveness[J]. Br J Cancer, 2001, 85 (6): 869-74.
[10] 徐工学,李志霞,陈佛来,等.术前区域性动脉灌注化疗对大肠癌细胞凋亡相关基因的影响[J].中华外科杂志,2001,39(6):436-9.Xu GX,Li ZX,Chen FL,et al.Changes in expression of apoptosis-regulating genes after preoperative chemotherapy with local intra-arterial infusion in patients with colorectal cancer[J].Chin J Surg,2001,39(6):436-9
[11] 王晓华,魏亚明,白海,等SeO2诱导白血病细胞凋亡及对凋亡相关基因Bcl-2和p53表达调控的影响[J].第一军医大学学报,2004,24(10):1160-3.Wang XH,Wei YM,Bai H,et al.Apoptosis and regulation of apoptosis-related gene Bcl-2 and p53 induced by selenium dioxide in three leukemia cell lines[J].J First Mil Med Univ/Di Yi Jun Yi Da Xue Xue Bao,2004,24(10):1160-3
[12] 候宝华,卿三华,张成德,等.热化疗联合5-Fu诱导大肠癌细胞凋亡和bcl-2表达[J].第一军医大学学报,2001,21(5):329-31.Hou BH,Qing SH,Zhang CD,et al.Apoptosis of and bcl-2expression in LoVo cell line induced by hyperthermia treatment combined with 5-Fu:an in vitro observation[J] J First Mil Med Univ/Di Yi Jun Yi Da Xue Xue Bao,2001,21(5):329-31
[13] 王西京,代志军,刘小旭,等.新辅助化疗对乳腺癌p53、bcl-2表达的影响及其意[J].西安交通大学学报(医学版),2003,24(4):379-81.Wang XJ, Dai ZJ, Liu XX, et al. The adjuvant to p53/bcl-2 and its implication of neoadjuvant chemotherapy in breast cancer[J]. J Xi’an Jiaotong Univ (Med Sci), 2003, 24(4): 379-81.
[14] Krajewski S, Blomqvist C, Franssila K, et al. Reduced expression of proapoptotic gene BAX is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma[J]. Cancer Res, 1995, 55 (19):4471-8.

[1]	LI Xin-an,AN Jing Department of Embryology and Histology,Southern Medical University,Guangzhou 510515,China. Mechanisms of the expression of exogenous genes injected via the mammary duct in rat mammary gland tissue [J]. Journal of Southern Medical University, 2006, 26(12): 1774-.
[2]	WU Wu-jun1,ZENG Jian2,PAN Cheng-en1 1Department of General Surgery,First Hospital of Xi’an Jiaotong University,Xi’an 710061,China;2Department of Gastrointestinal and Glands Surgery,First Affiliated Hospital,Guangxi Medical University,Nanning 530021,China. Efficacy of activated charcoal-epirubicin suspension for treatment of breast cancer with axillary metastasis [J]. Journal of Southern Medical University, 2006, 26(12): 1812-1814.
[3]	KANG Hua-feng,WANG Xi-jing,LIU Xiao-xu,DAI Zhi-jun,XUE Feng-jie,XUE Xing-huan Department of Oncological Surgery,Second Affiliated Hospital,School of Medicine,Xi’an Jiaotong University,Xi’an 710004,China. Chemopreventive effect of celecoxib against DMBA-induced breast cancer and its mechanism [J]. Journal of Southern Medical University, 2006, 26(11): 1599-1602.
[4]	LI Gui-ping1, ZHANG Yi-fan2, WANG Yong-xian3 1Departmant of Nuclear Medicine, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China; 2Department of Nuclear Medicine, Ruijin Hospital, Shanghai Second Medical University, Shanghai 200025, China; 3Radiopharmaceutical Research Center, Shanghai Institute of Applied Physics, Chinese Academy of Sciences, Shanghai 201800, China. 188Re-labeled herceptin inhibits proliferation of breast cancer cell line SKBR-3 in vitro [J]. Journal of Southern Medical University, 2006, 26(10): 1455-1457.
[5]	. [J]. Journal of Southern Medical University, 2006, 26(09): 1378-1379.
[6]	WANG Xiao-yu1, LIN Shao-qiang2, LI Jun-wu2, Kemmner Wolfgang3, DING Yan-qing4 Department of Obstetrics and Gynecology, First Affiliated Hospital of Ji’nan University1, Department of Microbiology and Immunology of Medical College2, Jinan University, Guangzhou 510630, China; 3Max-Delbrueck Center for Molecular Medicine,Berlin 13125, Germany; 4Institute of Oncology, Southern Medical University, Guangzhou 510515, China. Effect of cell surface sialic acid and their linkages on adhesion of mammary carcinoma cells [J]. Journal of Southern Medical University, 2006, 26(06): 742-746.
[7]	WANG Xiao-bing, YANG Qing-xu, PEI Xiao-juan Department of Pathology, Huizhou Central Hospital, Huizhou 516001, China. Expression of angiogenesis-related factors in invasive breast cancer and its clinical significance [J]. Journal of Southern Medical University, 2006, 26(06): 860-863.
[8]	HU Xiao-qu1,QIN Li1,SU Feng-xi1,YAO He-rui2,CHEN Ji-sheng1,GONG Chang1,GUO Ju-jiang1,YU Feng-yan1,JIA Hai-xia1 1Center of Breast Cancer,2Department of Oncology,Second Hospital of Sun Yat-sen University,Guangzhou 510272,China. Vector-mediated HER-2 RNA interference against HER-2-positive breast cancer [J]. Journal of Southern Medical University, 2006, 26(05): 570-572.
[9]	ZHANG Shu-qun1,ZHANG Shu-hui2,XUE Xin-huan1,WANG Xi-jing1,JIANG Jian-tao1 1Department of Oncology,Second Hospital,Xi’an Jiaotong University,Xi’an 710004,China;2Department of Chemical Engineering,Northwestern Polytechnical University,Xi’an 710072,China. Synergism between a siRNA targeted to survivin and 5-FU in inhibiting MCF-7 cell proliferation in vitro [J]. Journal of Southern Medical University, 2006, 26(03): 251-254.
[10]	FAN Yi-xiang,LUO Rong-Cheng,FANG Yong-Xin,YAN Xiao,Department of Oncology,Nanfang Hospital,Southern Medical University,Guangzhou 510515,China. Preparation,quality control and biodistribution of 131I-herceptin in New Zealand rabbits [J]. Journal of Southern Medical University, 2006, 26(03): 361-.
[11]	XU Lei, BAI Zhong-hong, XU Ruan-cheng, YAN Hui, WANG Fang-ju, LUO Rong-cheng Department of Oncology, 91 Hospital of PLA, Jiaozuo 454003, China;Oncology Center, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China. Expressions of Her-2, EGFR, PS-2 and ER in breast cancer and their clinical implications [J]. Journal of Southern Medical University, 2006, 26(02): 231-233.
[12]	TAN Ke, FAN Yi-xiang, MIAO Jing-xia, L(?) Cheng-wei, YAN Xiao, LUO Rong-cheng Center of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China. Killing effect of sequential Herceptin and adriamycin treatment on breast cancer cell line in vitro [J]. Journal of Southern Medical University, 2006, 26(02): 234-236.
[13]	CUI Fei, LUO Rong-cheng, CHEN Jin-zhang, CHEN Bin, HUANG Yu-xian. Therapeutic effect of TAX combined with Herceptin or epirubicin against breast cancer positive for Her-2/neu [J]. Journal of Southern Medical University, 2005, 25(12): 1533-1536.
[14]	LI Rong, ZHENG Hang, LUO Rong-cheng. Cloning and expression of the HER2 gene in MCF-7 cells [J]. Journal of Southern Medical University, 2005, 25(10): 1264-1267.
[15]	ZHENG Hang, LUO Rong-cheng. Diagnostic value of combined detection of TPS, CA153 and CEA in breast cancer [J]. Journal of Southern Medical University, 2005, 25(10): 1293-1294,1298.